Literature DB >> 1720426

Integrin expression in human melanoma cell lines: heterogeneity of vitronectin receptor composition and function.

J F Marshall1, S A Nesbitt, M H Helfrich, M A Horton, K Polakova, I R Hart.   

Abstract

Ten human melanoma cell lines were examined for integrin-receptor expression using a panel of antibodies directed against different integrin subunits. Considerable heterogeneity was detected for levels of expression of 7 integrins, including the alpha v beta 3 vitronectin receptor where a correlation between tumorigenic capacity in athymic nude mice and alpha v beta 3 levels was found. Detailed analysis of the vitronectin receptor on these lines revealed heterogeneity of composition. In one cell line, VUP, an alpha v beta 1 association was detected and, by antibody-inhibition studies, this receptor was shown to bind vitronectin as its ligand. In another line, DX3, evidence was obtained which indicated that apart from the alpha v beta 3 receptor the alpha v was able to associate with another beta subunit which was not beta 3. The existence of these alternative forms of the vitronectin receptor in this small sample of tumours of common origin might explain why the capacity to bind to fibrinogen and vitronectin substrates by these cells did not necessarily correlate with alpha v beta 3 levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720426     DOI: 10.1002/ijc.2910490621

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Cross talk between beta(1) and alpha(V) integrins: beta(1) affects beta(3) mRNA stability.

Authors:  S F Retta; G Cassarà; M D'Amato; R Alessandro; M Pellegrino; S Degani; G De Leo; L Silengo; G Tarone
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

2.  Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.

Authors:  M Y Hsu; D T Shih; F E Meier; P Van Belle; J Y Hsu; D E Elder; C A Buck; M Herlyn
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

3.  Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16.

Authors:  E Davison; R M Diaz; I R Hart; G Santis; J F Marshall
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Glycosylation modulates melanoma cell α2β1 and α3β1 integrin interactions with type IV collagen.

Authors:  Maciej J Stawikowski; Beatrix Aukszi; Roma Stawikowska; Mare Cudic; Gregg B Fields
Journal:  J Biol Chem       Date:  2014-06-23       Impact factor: 5.157

Review 5.  The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis.

Authors:  J Nip; P Brodt
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

6.  Selectin ligands on human melanoma cells.

Authors:  N Miller; R G Vile; I R Hart
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

7.  Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular processes in a concentration-dependent manner.

Authors:  Miriam Benezra; Evan Phillips; Michael Overholtzer; Pat B Zanzonico; Esa Tuominen; Ulrich Wiesner; Michelle S Bradbury
Journal:  Small       Date:  2014-12-03       Impact factor: 13.281

8.  Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin.

Authors:  J Nip; H Shibata; D J Loskutoff; D A Cheresh; P Brodt
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

9.  The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3.

Authors:  Steven B Ludbrook; Simon T Barry; Chris J Delves; Carmel M T Horgan
Journal:  Biochem J       Date:  2003-01-15       Impact factor: 3.857

10.  In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.

Authors:  Lynda Coughlan; Sabari Vallath; Antonio Saha; Magdalena Flak; Iain A McNeish; Georges Vassaux; John F Marshall; Ian R Hart; Gareth J Thomas
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.